• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Arteris Inc.

    2/12/26 5:20:23 PM ET
    $AIP
    Semiconductors
    Technology
    Get the next $AIP alert in real time by email
    S-8 1 d26067ds8.htm S-8 S-8

    As filed with the Securities and Exchange Commission on February 12, 2026

    Registration No. 333-

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    Arteris, Inc.

    (Exact name of Registrant as specified in its charter)

     

     

     

    Delaware   27-0117058

    (State or other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification Number)

    900 E. Hamilton Ave., Suite 300

    Campbell, CA

      95008
    (Address of Principal Executive Offices)   (Zip Code)

    2021 Incentive Award Plan

    2021 Employee Stock Purchase Plan

    Amended and Restated 2022 Employment Inducement Incentive Plan

    (Full Title of the Plan)

    K. Charles Janac

    Arteris, Inc.

    President and Chief Executive Officer

    900 E. Hamilton Ave., Suite 300

    Campbell, CA 95008

    (408) 470-7300

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:

     

    Phillip S. Stoup, Esq.

    Heather C. Brookfield, Esq.

    Freshfields US LLP

    One Bush Street, 17th Floor

    San Francisco, CA 94104

    Telephone: (415) 400-2200

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

    Proposed sale to take place as soon after the effective date of the

    registration statement as awards under the plans are exercised and/or vest.

     

     
     


    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

    The information called for in Part I of Form S-8 is not being filed with or included in this Form S-8 (by incorporation by reference or otherwise) in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

    In this Registration Statement, Arteris, Inc. is sometimes referred to as “Registrant,” “we,” “us” or “our.”

    REGISTRATION OF ADDITIONAL SECURITIES

    PURSUANT TO GENERAL INSTRUCTION E OF FORM S-8

    This Registration Statement on Form S-8 is filed by the Registrant, relating to (a) 2,213,440 shares of its common stock, $0.001 par value (the “Common Stock”), issuable to eligible employees, directors and consultants of the Registrant under the Registrant’s 2021 Incentive Award Plan (the “2021 Plan”), (b) 442,688 shares of Common Stock issuable to eligible employees of the Registrant under the Registrant’s 2021 Employee Stock Purchase Plan (the “ESPP”), and (c) 1,603,403 additional shares of Common Stock reserved for issuance under the Company’s Amended and Restated 2022 Employee Inducement Incentive Plan (the “Inducement Plan”). Shares available for issuance under the 2021 Plan, the ESPP, and the Inducement Plan were previously registered on registration statements on Form S-8 filed with the SEC on November 1, 2021, Registration No. 333-260620, March 7, 2022, Registration No. 333-263352, November 9, 2022, Registration No. 333-268258, March 1, 2023, Registration No. 333-270173, February 20, 2024, Registration No. 333-277200, and February 18, 2025, Registration No. 333-285039 (the “Prior Registration Statements”). The Prior Registration Statements are currently effective. This Registration Statement relates to securities of the same class as those to which the Prior Registration Statements relate and is submitted in accordance with Section E of the General Instructions to Form S-8 regarding Registration of Additional Securities. Pursuant to Section E of the General Instructions to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this Registration Statement, except as amended hereby.

    Item 3. Incorporation of Documents by Reference.

    The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this Registration Statement, and later information filed with the SEC will update and supersede this information. We hereby incorporate by reference into this Registration Statement the following documents previously filed with the SEC:

     

      •  

    the contents of the Registrant’s earlier Registration Statements on Form S-8 relating to the 2021 Plan and ESPP, previously filed with the SEC on November 1, 2021 (File No. 333-260620), March 7, 2022 (File No. 333-263352), March 1, 2023 (File No. 333-270173), February  20, 2024 (File No. 333-277200), and February  18, 2025 (File No. 333-285039);

     

      •  

    the contents of the Registrant’s earlier Registration Statement on Form S-8 relating to the Inducement Plan, previously filed with the SEC on November 9, 2022 (File No. 333-268258);

     

      •  

    the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 12, 2026;

     

      •  

    the information specifically incorporated by reference into the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024 from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 23, 2025; and

     

      •  

    the description of the Registrant’s Common Stock which is registered under Section 12 of the Exchange Act, in the Registrant’s Registration Statement on Form 8-A, filed on October 22, 2021, including any amendments or reports filed for the purposes of updating such description.


    All documents that the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to the registration statement which indicates that all of the shares of Common Stock offered have been sold or which deregisters all of such shares then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of the filing of such documents, except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, that is not deemed filed under such provisions. For the purposes of this Registration Statement, any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

    Under no circumstances will any information filed under current Items 2.02 or 7.01 of Form 8-K, and exhibits furnished on such form that relate to such items, be deemed incorporated herein by reference unless such Form 8-K expressly provides to the contrary.

    Item 8. Exhibits.

     

    Exhibit

    Number

            Incorporated by Reference    Filed
    Herewith
      

    Exhibit Description

       Form    Date    Number     
    4.1    Amended and Restated Certificate of Incorporation of Arteris, Inc.    8-K    10/29/21    3.1   
    4.2    Amended and Restated Bylaws of Arteris, Inc.    8-K    10/29/21    3.2   
    4.3    Specimen Stock Certificate evidencing the shares of common stock.    S-1/A    10/18/21    4.1   
    5.1    Opinion of Freshfields US LLP.             X
    23.1    Consent of Freshfields US LLP (included in Exhibit 5.1).             X
    23.2    Consent of Deloitte & Touche LLP, independent registered public accounting firm.             X
    24.1    Power of Attorney. Reference is made to the signature page to the Registration Statement.             X
    99.1#    2021 Incentive Award Plan.    S-8    10/29/21    99.2(a)   
    99.2#    Form of Stock Option Award Agreement under Arteris, Inc. 2021 Incentive Award Plan.    S-1/A    10/18/21    10.14   
    99.3#    Form of Restricted Stock Unit Award Agreement under Arteris, Inc. 2021 Incentive Award Plan    S-1/A    10/18/21    10.15   
    99.4#    Form of Performance Stock Unit Agreement under Arteris, Inc. 2021 Incentive Award Plan    10-K    02/12/26    10.21   
    99.5#    2021 Employee Stock Purchase Plan    S-8    10/29/21    99.3   
    99.6#    Amended and Restated 2022 Employment Inducement Incentive Plan    10-K    02/12/26    10.22   
    99.7#    Form of Stock Option Grant Notice and Stock Option Agreement under the 2022 Employment Inducement Award Plan    10-Q    11/8/22    10.3   
    99.8#    Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2022 Employment Inducement Award Plan    10-Q    11/8/22    10.4   
    107.1    Filing Fee Table             X

     

    #

    Indicates management contract or compensatory plan.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Campbell, State of California, on this 12th day of February, 2026.

     

    Arteris, Inc.
    By:  

    /s/ K. Charles Janac

      K. Charles Janac
      President and Chief Executive Officer

    POWER OF ATTORNEY

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Charles Janac and Nicholas B. Hawkins, and each of them, with full power of substitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.

     

    Signature    Title    Date

    /s/ K. Charles Janac

    K. Charles Janac

       President and Chief Executive Officer (Principal Executive Officer) and Chairman of the Board of Directors    February 12, 2026

    /s/ Nicholas B. Hawkins

    Nicholas B. Hawkins

      

    Vice President and Chief Financial Officer

    (Principal Financial and Accounting Officer)

       February 12, 2026

    /s/ Wayne C. Cantwell

    Wayne C. Cantwell

       Director    February 12, 2026

    /s/ Raman K. Chitkara

    Raman K. Chitkara

       Director    February 12, 2026

    /s/ Claudia Fan Munce

    Claudia Fan Munce

       Director    February 12, 2026

    /s/ Joachim Kunkel

       Director    February 12, 2026
    Joachim Kunkel      

    /s/ S. Atiq Raza

    S. Atiq Raza

       Director    February 12, 2026

    /s/ Antonio J. Viana

    Antonio J. Viana

       Director    February 12, 2026
    Get the next $AIP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AIP

    DatePrice TargetRatingAnalyst
    8/6/2025$12.00 → $15.00Buy
    TD Cowen
    9/1/2023$11.00 → $12.00Outperform
    TD Cowen
    3/4/2022$32.00 → $23.00Outperform
    Cowen
    11/22/2021$27.00Outperform
    Northland Capital
    11/22/2021$24.00Market Perform
    BMO Capital Markets
    11/22/2021$30.00Outperform
    Cowen
    11/22/2021$33.00Buy
    Jefferies
    11/22/2021$35.00Buy
    Rosenblatt
    More analyst ratings

    $AIP
    SEC Filings

    View All

    SEC Form S-3 filed by Arteris Inc.

    S-3 - Arteris, Inc. (0001667011) (Filer)

    2/12/26 5:22:41 PM ET
    $AIP
    Semiconductors
    Technology

    SEC Form S-8 filed by Arteris Inc.

    S-8 - Arteris, Inc. (0001667011) (Filer)

    2/12/26 5:20:23 PM ET
    $AIP
    Semiconductors
    Technology

    SEC Form 10-K filed by Arteris Inc.

    10-K - Arteris, Inc. (0001667011) (Filer)

    2/12/26 4:43:19 PM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Arteris Network-on-Chip Technology Achieves Deployment Milestone of 4 Billion Chips and Chiplets

    CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced that its technology has shipped in more than 4 billion devices, signifying important growth in enabling the underlying data movement for AI-era chips and chiplets. While Arteris system IP has long been deployed in high-volume devices, from automotive systems to consumer devices, recent growth has been driven by increased adoption in AI-enabled systems, where Arteris technology is particularly suited for rising compute density, energy efficiency requirements, chiplet integration, and ever-growing system com

    2/12/26 4:10:00 PM ET
    $AIP
    Semiconductors
    Technology

    Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Year 2026 Guidance

    CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance. "In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus royalties reaching $83.6 million, representing 28% year-over-year growth. During the quarter, our customers surpassed the milestone of more than four billion systems shipped with SoCs connected by Arteris System IP, and we enjoyed royalty gr

    2/12/26 4:05:00 PM ET
    $AIP
    Semiconductors
    Technology

    Arteris Technology Deployed More Broadly by NXP to Accelerate Edge AI Leadership

    CAMPBELL, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced that NXP® Semiconductors has expanded its use of Arteris system IP products across its AI-enabled silicon solutions. These solutions enable intelligent vehicles, advanced industrial systems, and secure, seamless consumer experiences on the edge. NXP's "Brighter Together" approach combines leading-edge technology with pioneering people to develop system solutions that make the connected world better, safer and more secure. They have successfully leveraged Arteris products to enable safe and secure data move

    2/11/26 4:05:00 PM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bayview Legacy, Llc sold $759,788 worth of shares (50,000 units at $15.20) (SEC Form 4)

    4 - Arteris, Inc. (0001667011) (Issuer)

    2/11/26 8:05:43 PM ET
    $AIP
    Semiconductors
    Technology

    President and CEO Janac K Charles sold $759,788 worth of shares (50,000 units at $15.20) (SEC Form 4)

    4 - Arteris, Inc. (0001667011) (Issuer)

    2/11/26 7:01:04 PM ET
    $AIP
    Semiconductors
    Technology

    VP and General Counsel Alpern Paul L exercised 5,000 shares at a strike of $0.56 and sold $77,376 worth of shares (5,000 units at $15.48) (SEC Form 4)

    4 - Arteris, Inc. (0001667011) (Issuer)

    2/4/26 4:58:24 PM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    TD Cowen reiterated coverage on Arteris with a new price target

    TD Cowen reiterated coverage of Arteris with a rating of Buy and set a new price target of $15.00 from $12.00 previously

    8/6/25 7:10:46 AM ET
    $AIP
    Semiconductors
    Technology

    TD Cowen reiterated coverage on Arteris with a new price target

    TD Cowen reiterated coverage of Arteris with a rating of Outperform and set a new price target of $12.00 from $11.00 previously

    9/1/23 7:31:29 AM ET
    $AIP
    Semiconductors
    Technology

    Cowen reiterated coverage on Arteris with a new price target

    Cowen reiterated coverage of Arteris with a rating of Outperform and set a new price target of $23.00 from $32.00 previously

    3/4/22 7:21:31 AM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Financials

    Live finance-specific insights

    View All

    Arteris Announces Financial Results for the Fourth Quarter and Full Year 2025 and Estimated First Quarter and Full Year 2026 Guidance

    CAMPBELL, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of semiconductor technology for accelerating innovation in the AI era, today announced financial results for the fourth quarter and year ended December 31, 2025 and provided estimated first quarter and full year 2026 guidance. "In the fourth quarter of 2025, we again delivered strong financial results, including a new record of Annual Contract Value plus royalties reaching $83.6 million, representing 28% year-over-year growth. During the quarter, our customers surpassed the milestone of more than four billion systems shipped with SoCs connected by Arteris System IP, and we enjoyed royalty gr

    2/12/26 4:05:00 PM ET
    $AIP
    Semiconductors
    Technology

    Arteris to Announce Financial Results for the Fourth Quarter and Year End 2025 on Thursday, February 12, 2026

    CAMPBELL, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading technology provider for accelerating semiconductor creation in the AI era, today announced it will release its financial results for the fourth quarter and full year ended December 31, 2025, after market close on Thursday, February 12, 2026. Management will host a conference call on Thursday, February 12, 2026, at 4:30 PM ET to discuss these results. The call will be available, live, to interested parties by dialing: United States/Canada Toll Free:+1-800-717-1738International Toll:+1-646-307-1865 Please join the call 5-10 minutes prior to the scheduled start time to avoid a delay in connecting. A liv

    2/2/26 4:05:00 PM ET
    $AIP
    Semiconductors
    Technology

    Arteris Announces Financial Results for the Third Quarter and Estimated Fourth Quarter and Updated Full Year 2025 Guidance

    CAMPBELL, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of semiconductor system IP for accelerating system-on-chip (SoC) creation, today announced financial results for the third quarter ended September 30, 2025 and provided estimated fourth quarter and updated full year 2025 guidance. "In the third quarter of 2025, we achieved another record with Annual Contract Value plus royalties of $74.9 million, up 24% year-over-year. In addition, we exited the quarter with $104.7 million in Remaining Performance Obligations, up 34% year-over-year and exceeding $100.0 million for the first time in our history," said K. Charles Janac, President and CEO of Ar

    11/4/25 4:06:00 PM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Leadership Updates

    Live Leadership Updates

    View All

    Joachim Kunkel Joins Arteris Board of Directors

    CAMPBELL, Calif., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Arteris, Inc. (NASDAQ:AIP), a leading provider of system IP which accelerates system-on-chip (SoC) creation, today announced that Joachim Kunkel will join its Board of Directors. Mr. Kunkel most recently served as the General Manager of the Intellectual Property (IP) business unit at Synopsys where he grew Synopsys' IP revenue to over $1.5 billion, making Synopsys the second largest semiconductor IP company in the world. With three decades of experience at Synopsys, Mr. Kunkel brings a wealth of knowledge and leadership to Arteris. Prior to joining Synopsys, Joachim Kunkel co-founded and served as managing director of CADIS GmbH, where

    9/16/24 5:00:00 PM ET
    $AIP
    Semiconductors
    Technology

    $AIP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Arteris Inc.

    SC 13G/A - Arteris, Inc. (0001667011) (Subject)

    11/13/24 4:32:26 PM ET
    $AIP
    Semiconductors
    Technology

    SEC Form SC 13G filed by Arteris Inc.

    SC 13G - Arteris, Inc. (0001667011) (Subject)

    6/27/24 3:46:24 PM ET
    $AIP
    Semiconductors
    Technology

    SEC Form SC 13G/A filed by Arteris Inc. (Amendment)

    SC 13G/A - Arteris, Inc. (0001667011) (Subject)

    1/24/24 4:05:55 PM ET
    $AIP
    Semiconductors
    Technology